Abstracts tagged "Sjogren’s syndrome and tocilizumab"

Abstract Number: 1904 • 2019 ACR/ARP Annual Meeting
IL-6 Receptor Inhibition in Primary Sjögren Syndrome : Results from a Randomized Multicenter Academic Double Blind Placebo-controlled Trial of Tocilizumab in 110 Patients
Renaud Felten ¹, Nicolas Meyer ¹, P Duffaut ², D Saadoun ³, Eric Hachulla ⁴, Pierre Yves Hatron ⁴, Carine Salliot ⁵, Aleth Perdriger ⁶, Jacques Morel ⁷, Arsène Mekinian ⁸, Olivier Vittecoq ⁹, Jean Marie Berthelot ¹⁰, Emmanuelle Dernis ¹¹, Véronique Le Guern ¹², Philippe Dieudé ¹³, Claire Larroche ¹⁴, Christophe Richez ¹⁵, Thierry Martin ¹, Charles Zarnitsky ¹⁶, Gilles Blaison ¹⁷, P Kieffer ¹⁸, François Maurier ¹⁹, Stéphanie Rist ⁵, Patrice Cacoub ²⁰, Emmanuel Andres ²¹, Emmanuel Chatelus ¹, Christelle Sordet ¹, Jean Sibilia ¹, Cécile Arnold ¹, Mira Tawk ¹, Ouafaa Aberkane ¹, Raphaele Seror ²², Lise Holterbach ¹, Xavier Mariette ²² and Jacques-Eric Gottenberg²³, ¹Strasbourg University Hospital, Strasbourg, France, ²Bordeaux University Hospital, Bordeaux, Aquitaine, France, ³Pitie Salpetrière Hospital, APHP, Paris, France, ⁴Lille University Hospital, Lille, France, ⁵Orleans Hospital, Orleans, France, ⁶Rennes University Hospital, Rennes, France, ⁷Montpellier University Hospital, Montpellier, France, ⁸Saint-Antoine Hospital, APHP, Paris, France, ⁹Rouen University Hospital, ROUEN, France, ¹⁰Nantes University Hospital, Nantes, France, ¹¹Le Mans Hospital, Le Mans, France, ¹²Cochin Hospital, APHP, PARIS, France, ¹³Bichat Hospital, APHP, PARIS, ¹⁴Avicenne Hospital, PARIS, France, ¹⁵Bordeaux University Hospital, Bordeaux, France, ¹⁶Le Havre Hospital, Le Havre, ¹⁷Colmar Hospital, Colmar, France, ¹⁸Mulhouse Hospital, Mulhouse, France, ¹⁹Metz Hospital, Metz, France, ²⁰Pitie Salpéterière, APHP, Paris, France, ²¹CHU Strasbourg, strasbourg, ²²Bicetre Hospital, APHP, Paris, France, ²³Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France
Background/Purpose: IL-6 is suspected to play an important pathogenic role in primary Sjögren’s syndrome (pSS) through its crucial roles in B-cell activation, and T-cell polarization,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].